Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis Q1 hit by H1N1

Sanofi-aventis has seen its first-quarter financial results hit by lack of flu vaccine and generic competition

Sanofi-aventis (SA) has reported a 16.1 per cent fall in net income to €2.2bn at CER for the first quarter of 2011.

The company posted a 5.2 per cent decline in first-quarter sales to €7.8bn in 2011, including €569m of sales lost in 2011 due to generic competition,.

However, excluding A/H1N1 sales its first-quarter sales rose by 0.1 per cent.

The company said emerging markets sales increased by 14.6 per cent (excluding A/H1N1 sales) to €2.4bn, exceeding the US and Western Europe, and accounted for 30.7 per cent of group sales.

Christopher A Viehbacher, CEO, S-A, said: "This quarter, the year-on-year comparison must take into account the absence of non-recurring A/H1N1 sales. I'm particularly satisfied with the performance of our growth platforms which were up 15.5 per cent (excluding A/H1N1) and now represent almost 60 per cent of group sales; these businesses have compensated for the impact of generic competition on net sales and represent the future of our company."

S-A's EPS was €1.66, down 16.1 per cent at CER. Excluding A/H1N1 sales, the decrease in business EPS was limited to 6.0 per cent at CER.

28th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics